ReviewOncology letters2025
Application of multivalent aptamers in tumor diagnosis, analysis and therapy (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Stability modification of therapeutic aptamers: from biostability bottlenecks to nuclease-resistant construct design.RSC chemical biology · 2026Review
- Editorial: Emerging targeted and immunotherapeutic strategies in oncology: from solid tumors to hematologic malignancies.Frontiers in pharmacology · 2026Article
- Review
- Synthesis and characterization of a isothiouronium-calix[4]arene derivative: self-assembly and anticancer activity.Beilstein journal of organic chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the leading causes of mortality worldwide, making early diagnosis and precise treatment crucial for enhancing patient survival rates. Previously, nucleic acid aptamers have emerged as promising tools in tumor diagnosis, analysis and therapy, owing to their high specificity, cost-effectiveness and ease of modification. Unlike monovalent aptamers, multivalent aptamers markedly improve target affinity and specificity through multipoint binding, demonstrating superior efficacy in the detection, capture and treatment of tumor cells. The present study reviews the construction methods of multivalent aptamers, their applications in tumor diagnosis and therapy and their challenges and prospects. Constructed through nucleic acid nanostructure self-assembly, bio-coupling, nanomaterial loading and chemical cross-linking, multivalent aptamers can effectively detect circulating tumor cells, enabling the non-invasive release of tumor cells. They serve as alternatives to bispecific antibodies in tumor immunotherapy. Despite challenges in specificity,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.